Welcome to our dedicated page for Stevanato Group S P A news (Ticker: STVN), a resource for investors and traders seeking the latest updates and insights on Stevanato Group S P A stock.
Stevanato Group S.p.A. (NYSE: STVN) is a global provider of drug containment, drug delivery, and diagnostic solutions for pharmaceutical, biotechnology, and life sciences companies. Its news flow, as reflected in recent press releases and SEC filings, centers on financial performance, capacity expansion, financing arrangements, and participation in healthcare investor conferences.
Investors following STVN news will find regular quarterly earnings announcements detailing revenue trends, segment performance for the Biopharmaceutical and Diagnostic Solutions and Engineering segments, margin evolution, and the growing contribution of high-value solutions such as high-performance Nexa® syringes and EZ-fill® vials and cartridges. These updates often include discussion of non-GAAP measures, capital expenditures, and liquidity.
News coverage also highlights strategic investments and footprint optimization, including expansions at manufacturing facilities in Cisterna di Latina and Fishers to increase pre-filled syringe and ready-to-use cartridge capacity, and enhancements at the Bad Oeynhausen, Germany, site for drug delivery system production. Financing news, such as the €200 million agreements with BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM, provides additional context on how Stevanato Group funds these projects.
In addition, Stevanato Group frequently announces its participation in major healthcare and investor conferences in locations such as New York, London, Las Vegas, Chicago, and Vienna. These events offer further insight into management’s views on market dynamics, high-value solutions, and long-term strategy.
By monitoring this page, readers can track Stevanato Group’s latest earnings releases, operational updates on capacity expansion and optimization plans, financing developments, and investor relations activities, all drawn from company-issued news and regulatory communications.
Stevanato Group (NYSE: STVN) will participate in the KeyBanc Capital Markets Virtual Healthcare Forum on Tuesday, March 17 and Wednesday, March 18, 2026. The company will present on March 17 at 9:45-10:20 a.m. ET.
A live webcast will be available on the company’s Investors page, with a replay accessible for approximately 90 days after the event.
Stevanato Group (NYSE: STVN) reported FY2025 revenue of €1.186 billion (+7% reported; +9% constant currency) and record demand for high-value solutions. Gross profit margin expanded to 29.0% and adjusted EBITDA margin to 25.1%. Diluted EPS rose 19% to €0.51.
The company logged Q4 revenue of €346.5 million, Q4 high-value solutions of €171.4 million (49% of revenue), cash of €130.6 million, net debt of €337.7 million, and reported positive free cash flow of €18.4 million for 2025. Fiscal 2026 guidance: revenue €1.26–1.29 billion; adjusted EBITDA €331.8–346.9 million; adjusted diluted EPS €0.59–0.63.
Stevanato Group (NYSE: STVN) will report fourth quarter and fiscal year 2025 results on Wednesday, March 4, 2026 with results issued at 6:30 a.m. ET and a conference call and webcast at 8:30 a.m. ET. The company said a slide presentation will be posted the morning of the call and the webcast will be archived for three months.
Stevanato Group (NYSE: STVN) reported Q3 2025 revenue of €303.2M, up 9% YoY (11% constant currency), with record high-value solutions at €147.9M (49% of revenue).
Gross profit margin rose 240 bps to 29.2%, adjusted EBITDA margin improved 280 bps to 25.7%, and adjusted diluted EPS was €0.14. BDS segment revenue grew 14% to €266.7M, while Engineering revenue fell 19% to €36.4M. Cash was €113.3M and net debt €333M; Q3 free cash flow was €0.3M.
The company maintained fiscal 2025 guidance: revenue €1.160–1.190B, adjusted EBITDA €288.5–301.8M, and adjusted diluted EPS €0.50–0.54.
Stevanato Group (NYSE: STVN) will participate in two investor conferences in mid-November 2025. The company will present at The 7th Annual Wolfe Research Healthcare Conference in New York on Monday, November 17, 2025 at 8:40 a.m. ET and at The Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 11:00 a.m. GMT.
A live webcast of each presentation will be available on the company website under Investors, with replays accessible for approximately 90 days after each event.
Stevanato Group (NYSE: STVN) will report third quarter 2025 financial results on Thursday, November 6, 2025 at 6:30 a.m. ET. The company will host a conference call and live webcast at 8:30 a.m. ET the same day to discuss results, accompanied by a slide presentation available on the company’s Investor Relations "Financial Results" page the morning of the call.
Participants may pre-register to receive a passcode and unique PIN to bypass the operator. A listen-only webcast will be available, dial-in numbers are provided for Italy, the UK, and the US, and the webcast will be archived on the Investor Relations site for three months.
Stevanato Group (NYSE: STVN) announced on October 21, 2025 a multi‑million investment to expand drug delivery system manufacturing at its Bad Oeynhausen, Germany site.
The project adds >2,500 square meters of advanced production space with an ISO 8 cleanroom, injection molding and automated assembly to support proprietary devices and contract manufacturing. Key platforms named are the Aidaptus autoinjector and Alina pen injector. The upgrade aims to strengthen European supply‑chain integration and combine glass primary packaging, analytical services, and equipment manufacturing to improve flexibility, scalability, and speed‑to‑market for pharma and biotech partners.
Stevanato Group (NYSE: STVN), a leading provider of drug containment, delivery, and diagnostic solutions, has announced its participation in two major investor conferences in September 2025:
The company will present at the 23rd Annual Morgan Stanley Global Healthcare Conference in New York City on September 9, 2025, at 7:45 a.m. ET, and at the Bank of America Global Healthcare Conference in London on September 24, 2025, at 10:45 a.m. BST.
Live webcasts will be available on the company's website, with replays accessible for approximately 90 days after each event.
Stevanato Group (NYSE:STVN) reported strong Q2 2025 financial results with revenue increasing 8% to €280.0 million. The company's high-value solutions represented 42% of total revenue, reaching €116.8 million. The Biopharmaceutical and Diagnostic Solutions (BDS) segment grew 10%, while the Engineering segment declined 2%.
Key financial metrics showed improvement with gross profit margin increasing 210 basis points to 28.1% and adjusted EBITDA margin rising 240 basis points to 23.2%. The company maintained its fiscal 2025 guidance, expecting revenue between €1.160-1.190 billion and adjusted diluted EPS of €0.50-0.54.
Stevanato Group (NYSE: STVN) has secured €200 million in financing through agreements with multiple banks to support its capital expenditure projects. The funding breakdown includes €100 million from BNL BNP Paribas, €50 million from CDP, and €50 million from Banco BPM.
The financing will support expansion projects at the company's facilities in Cisterna di Latina (Italy) and Fishers (Indiana, U.S.). The funds will be used to enhance pre-filled syringe production, set up ready-to-use (RTU) cartridge capacity, and complete device manufacturing construction, supporting the company's growing biologics programs.